Why StemCells (STEM) Hit a One-Year High Today

Posted: June 21, 2014 at 3:45 pm

Update (4:20 p.m.): Updated with Thursday market close information.

NEW YORK (TheStreet) --StemCells (STEM) surged to a 52-week high of $2.10 on Thursday after the company reported positive interim results from a Phase I/II clinical trial of itsproprietary HuCNS-SC human neural stem cell platform in dry age-related macular degeneration.

The results showed improvement in visual function and a slowing of the disease's progression. The data showed a65% decrease in the rate of geographic atrophy in the eye studied compared to the expected natural history of the disease, along with a 70% decrease in the rate of GA (the gradual loss of two crucial retinal tissue layers, the photoreceptors and the retinal pigmented epithelium) when compared to the control eye.

Maxim Groupsaid in a research note Thursday the early data "represents a best case outcome. This therapy represents a blockbuster opportunity (dry AMD) and could be transformational for the company."Maxim maintained its "buy" rating and $2.50 price target on the stock.

STEM data by YCharts

See more here:
Why StemCells (STEM) Hit a One-Year High Today

Related Posts